As of Feb 17
| +0.08 / +0.76%|
The 5 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 11.00, with a high estimate of 14.00 and a low estimate of 11.00. The median estimate represents a +3.58% increase from the last price of 10.62.
The current consensus among 5 polled investment analysts is to Buy stock in Progenics Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.